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The recently identified host restriction factor tetherin (BST-2, CD317) potently 30 
inhibits the release of nascent retrovirus particles from infected cells. 31 
Recently, we reported the identification and characterization of tetherin as a 32 
novel feline retroviral restriction factor. Based on homology to human tetherin 33 
we identified a putative tetherin gene in the genome of the domestic cat (Felis 34 
catus) which was found to be expressed in different feline cell lines both prior 35 
to and post treatment with either type I or type II interferon (IFN). The 36 
predicted structure of feline tetherin (feTHN) was that of a type II single-pass 37 
transmembrane protein encoding an N-terminal transmembrane anchor, 38 
central predicted coiled-coil bearing extracellular domain to promote 39 
dimerization, and a C-terminal GPI-anchor, consistent with conservation of 40 
structure between human and feline tetherin. FeTHN displayed potent 41 
inhibition of feline immunodeficiency virus (FIV) and human immunodeficiency 42 
virus type 1 (HIV-1) particle release in single-cycle replication assays. 43 
Notably, feTHN activity was resistant to antagonism by HIV-1 Vpu. However, 44 
stable ectopic expression of feTHN mRNA in different feline cell lines had no 45 
inhibitory effect on the growth of diverse primary or cell culture-adapted 46 
strains of FIV. Hence, whereas feline tetherin efficiently blocks viral particle 47 
release in single-cycle replication assays, it might not prevent dissemination of 48 
feline retroviruses in vivo.  49 




1. Introduction 53 
 54 
Feline immunodeficiency virus (FIV) is an important global lentiviral pathogen 55 
that infects both domestic and nondomestic felids (Brown et al., 1993, 1994; 56 
Carpenter et al., 1996; Hofmann-Lehmann et al., 1996; Troyer et al., 2004, 57 
2005). FIV infection of domestic cats (Felis catus) results in a fatal 58 
immunodeficiency syndrome similar to AIDS in humans infected with human 59 
immunodeficiency virus (HIV) (Pedersen et al., 1987, 1989; Yamamoto et al., 60 
1988; Pedersen, 1993; Bendinelli et al., 1995). The virus-induced gradual 61 
immunological deterioration leads to common clinical signs such as recurrent 62 
gingivitis and stomatitis, lymphoma, loss of condition (cachexia/wasting), 63 
neurological disorders and high mortality in infected cats (Pedersen et al., 64 
1987; Hosie et al., 1989; Sparger et al., 1989; Yamamoto et al., 1989; Ackley 65 
et al, 1990; Torten et al., 1991; Callanan et al., 1992, 1996; Pedersen, 1993). 66 
Because of the high degree of similarity between the genomic organization, 67 
the mode of transmission and the pathology of HIV and FIV infections, the 68 
domestic cat has been established as the smallest natural animal model for 69 
studying the development of AIDS in humans and for evaluating potential 70 
intervention strategies (Willett et al,, 1997; Miller et al., 2000; Troyer et al., 71 
2004).  72 
The ability of retroviruses to initiate a complex array of interactions with host 73 
cell proteins and other factors is a critical determinant of cell tropism, 74 
successful replication and persistence within the host. The majority of these 75 
host-virus interactions are beneficial for the virus (Malim, 2009). In recent 76 
years, however, a group of intracellular proteins has been identified that 77 
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specifically evolved to interfere with viral replication. These proteins are 78 
collectively called restriction factors and form a separate branch of the innate 79 
immunity termed intrinsic immunity (Bieniasz, 2004; Goff, 2004). Restriction 80 
factors affect almost all stages of the viral lifecycle (Bieniasz, 2004), such as 81 
uncoating, reverse transcription, nuclear entry and egress, and their cell-type 82 
and species-specific expression and activity control the viral host spectrum 83 
and may impose a barrier to cross-species transmission events (Troyer et al., 84 
2008). In order to efficiently replicate and to evade immune surveillance, 85 
retroviruses have to overcome this line of defense and, thus, have evolved 86 
proteins that antagonize the actions of restriction factors or mechanisms to 87 
avoid them.  88 
A better understanding of the interactions between host restriction factors and 89 
their viral antagonists will help to improve animal models for infection and to 90 
facilitate the identification of potential targets for antiviral therapies as well as 91 
retroviral gene delivery. 92 
 93 
2. Restriction factors to retroviral replication 94 
 95 
The longest (alpha) isoform of TRIM5, a member of the tripartite interaction 96 
motif family of proteins (Reymond et al., 2001, Stremlau et al., 2004), and 97 
APOBEC3 (apolipoprotein B mRNA-editing catalytic polypeptide 3) proteins, a 98 
family of cellular polynucleotide cysteine deaminases (Teng et al., 1993; 99 
Sheehy et al., 2002; Mangeat et al., 2003; Zhang et al., 2003), constitute the 100 
so-called early post-entry blocks to retroviral infection and have been well 101 
characterized in humans, non-human primates and domestic cats.   102 
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TRIM5α binds to the incoming retroviral capsid (CA) in the cytoplasm via its 103 
C-terminal PRY/SPRY (B30.2) domain (Mische et al., 2005; Sebastian and 104 
Luban, 2005; Stremlau et al., 2006; Langelier et al., 2008) and the resulting 105 
capsid/TRIM5α complex is incapable of completing reverse transcription 106 
(Keckesova et al., 2004; Stremlau et al., 2004). Instead, the N-terminal RBCC 107 
(RING, B-box and coiled coil) domain of TRIM5α possesses E3 ubiquitin 108 
ligase activity (RING) (Yamauchi et al., 2008) and ubiquination of the complex 109 
targets it for proteosome-mediated degradation (Diaz-Griffero et al., 2006; 110 
Towers, 2007). It has been proposed that TRIM5α may accelerate or abrogate 111 
viral uncoating (Stremlau et al., 2006) which not only inhibits reverse 112 
transcription but also nuclear import of viral cDNA (Berthoux et al., 2004; Wu 113 
et al, 2006). Previously, we reported that the TRIM5 transcript in cat cells 114 
possesses a truncation in the B30.2 capsid binding domain, which ablates its 115 
restrictive function (McEwan et al., 2009).  116 
The antiviral activity of APOBEC3 proteins was discovered through the study 117 
of the HIV-1 accessory protein Vif (viral infectivity factor) (Wolf and Goff, 118 
2008) which was shown to be dispensable for viral replication in certain 119 
permissive cell lines such as CEM-SS and SupT1, but absolutely required in 120 
non-permissive cells such as primary CD4+ T cells, monocyte-derived 121 
macrophages, and some T cell leukemia lines such as CEM (Fisher et al., 122 
1987; Strebel et al., 1987; Gabuzda et al., 1992; Sakai et al., 1993; Sova and 123 
Volsky, 1993). The human APOBEC3G protein (A3G; initially called CEM-15) 124 
was identified as the responsible cellular factor whose expression renders 125 
human cells non-permissive for infection by HIV-1 strains devoid of the Vif 126 
gene, but not by Vif-proficient HIV-1 strains (Sheehy et al., 2002). A3G 127 
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belongs to a large family of cytosine deaminases (reviewed in Harris and 128 
Liddament, 2004; Conticello et al., 2007; Holmes et al., 2007; Aguiar and 129 
Peterlin, 2008; Conticello, 2008; Goila-Gaur and Strebel, 2008) that catalyze 130 
the hydrolysis of cytosines to uracils. In order to carry out its anti-viral activity, 131 
A3G has to be packaged into Vif-deficient virions as they are formed in 132 
producer cells (Sheehy et al., 2002; Harris et al., 2003; Lecossier et al., 2003; 133 
Mangeat et al., 2003; Zhang et al., 2003). A3G is then carried to the target 134 
cell, where it, upon initiation of reverse transcription, deaminates cytosine 135 
residues in nascent retroviral minus-strand cDNA to uracils. Subsequently, the 136 
uracils function as a template for the incorporation of plus-strand adenines 137 
resulting in guanine to adenine hypermutations in the viral genome that 138 
critically affect viability and infectivity of the virus (Harris et al., 2003; Mangeat 139 
et al., 2003; Zhang et al., 2003; Bishop et al., 2004; Liddament et al., 2004; 140 
Zheng et al., 2004). Recent studies propose that, in addition to deamination, 141 
deamination-independent mechanisms of A3G to inhibit viral replication exist 142 
(Shindo et al., 2003; Newman et al., 2005; Guo et al., 2006, 2007; Iwatani et 143 
al., 2006, 2007; Opi et al., 2006; Bishop et al., 2006; Holmes et al., 2007; Li et 144 
al., 2007; Yang et al., 2007). These affect multiple stages of the reverse 145 
transcription and collectively impair the accumulation of reverse transcription 146 
products (Mangeat et al., 2003, Guo et al., 2006, 2007; Iwatani et al., 2007; Li 147 
et al., 2007; Luo et al., 2007; Mbisa et al., 2007). 148 
The primary role of Vif is to prevent A3G incorporation into virions. It targets 149 
A3G for proteasome-mediated degradation (Conticello et al., 2003; Marin et 150 
al., 2003; Sheehy et al., 2003; Stopak et al., 2003; Liu et al., 2004, 2005; 151 
Mehle et al., 2004a, 2004b) by bridging an interaction between A3G and a 152 
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ubiquitin E3 ligase complex consisting of elongins B and C, cullin 5 and ring-153 
box-1 (Yu et al., 2003; Yu et al., 2004; Mehle et al., 2004b, Bergeron, 2010). 154 
The interaction between A3G and Vif is species-specific and partly determines 155 
the host range of a virus (Hatziioannou et al., 2006).  156 
Several APOBEC3 genes have recently been identified and characterized in 157 
the genome of domestic cats (Münk et al., 2008). The A3 gene locus encodes 158 
three highly similar A3C (A3Z2) genes and an A3H (A3Z3) gene. Additionally, 159 
a fifth transcript, which is generated by read-through alternative splicing, 160 
encodes the protein A3CH (A3Z2-Z3) (Münk et al., 2008; Zielonka et al., 161 
2010). The feline A3 proteins display different degrees of activity against feline 162 
retroviruses. Feline A3C proteins inhibit the replication of Bet-deficient feline 163 
foamy virus (FeFV) but do not restrict Vif-deficient FIV or feline leukemia virus 164 
(FeLV). In contrast, feline A3H and A3CH proteins are active against Vif-165 
deficient FIV as well as FeLV but not against Bet-deficient FeFV (Löchelt et 166 
al., 2005; Münk et al., 2008). Feline A3 proteins are overcome by the FIV Vif 167 
and the FeFV Bet protein (Löchelt et al., 2005; Münk et al., 2008; Stern et al., 168 
2010; Zielonka et al., 2010).  169 
In addition to the early post-entry blocks, restriction factors such as tetherin 170 
contribute to a late block to retroviral replication in that they prevent the 171 
release of mature enveloped viral particles from the membranes of infected 172 
cells. Tetherin (also called HM1.24/BST-2/CD317) was originally identified as 173 
a bone marrow stromal cell surface antigen selectively expressed on 174 
terminally differentiated normal and neoplastic human B cells and 175 
corresponding cell lines (Goto et al., 1994, Ishikawa et al., 1995). Several 176 
studies have shown that tetherins are novel type II transmembrane proteins 177 
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with a molecular weight of 30-36 kDa (Ishikawa et al., 1995; Ohtomo et al., 178 
1999, Kupzig et al., 2003). They harbour an N-terminal cytoplasmic tail, 179 
followed by a transmembrane domain, an extracellular parallel, dimeric, alpha-180 
helical coiled coil domain and a C-terminal glycosyl-phosphatidylinositol (GPI) 181 
anchor (Ishikawa et al., 1995; Ohtomo et al., 1999; Kupzig et al., 2003, 182 
Rollason et al., 2007; Hinz et al., 2010). Two potential N-linked glycosylation 183 
sites and three conserved cysteine residues are present in the extracellular 184 
domain (Ishikawa et al., 1995; Ohtomo et al., 1999; Kupzig et al., 2003). 185 
Heterogeneous glycosylation of tetherin has been shown to be essential for 186 
efficient secretion and folding (Andrew et al., 2009; Goffinet et al., 2009; 187 
Kaletsky et al., 2009; McNatt et al., 2009; Miyagi et al., 2009; Perez-Caballero 188 
et al., 2009). The cysteines take part in intra- and intermolecular disulfide 189 
bond formation and enable the homodimerization of tetherins (Ohtomo et al., 190 
1999, Kupzig et al., 2003; Perez-Caballero et al., 2009). The GPI-modification 191 
causes tetherin to partition into and cross-link cholesterol- and sphingolipid-192 
rich microdomains in the plasma membrane (Simons and Ikonen, 2000; 193 
Simons and Toomre, 2000, Kupzig et al., 2003). Tetherin cycles between the 194 
lipid rafts on the cell surface and an intracellular pool where it localizes 195 
predominantly to the Golgi apparatus, the trans-Golgi network (TGN) and 196 
recycling endosomes (Kupzig et al., 2003). Internalization from the plasma 197 
membrane is mediated by clathrin-dependent endocytosis (Rollason et al., 198 
2007; Masuyama et al., 2009).  199 
The antiviral activity of tetherin was not discovered until 2008, when it was 200 
noted that its cell-type specific expression matched closely the dependency of 201 
HIV-1 on the accessory protein Vpu (viral protein U) for virus release from 202 
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certain human cell lines (Strebel et al., 1989; Terwilliger et al., 1989; Klimkait 203 
et al., 1990; Varthakavi et al., 2003; Neil et al., 2008; Van Damme et al., 204 
2008). Tetherin is constitutively expressed in human cell lines such HeLa cells 205 
(Gottinger et al., 1993), several cancer cell lines (Ohtomo et al., 1999), B 206 
cells, T cells, monocytes, macrophages and plasmacytoid dendritic cells 207 
(Vidal-Laliena et al., 2005; Blasius et al., 2006; Miyagi et al., 2009) and its 208 
expression is induced or enhanced by type I and type II interferons (IFN) in 209 
cell lines such as HOS, 293T, HT1080 cells (Neil et al., 2006, 2007, 2008; 210 
Van Damme et al., 2008; Miyagi et al., 2009). Interferon treatment renders cell 211 
lines that do not normally require Vpu for efficient virus release Vpu-212 
dependent (Neil et al., 2007).   213 
Tetherin causes the retention of fully formed, mature virions on the surface of 214 
cells infected with Vpu-deficient HIV-1 (Neil et al., 2008; Van Damme et al., 215 
2008). At the expense of particle release, virions accumulate at the cell 216 
surface and a fraction of them are endocytosed via a clathrin-dependent 217 
mechanism and degraded (Neil et al., 2006, 2007, Miyakawa et al., 2009). 218 
Current models predict that tetherin is present at sites of particle assembly in 219 
the cell membrane and is incorporated into virions (Perez-Caballero et al., 220 
2009; Fitzpatrick et al., 2010). Presumably, one end of tetherin embeds in the 221 
lipid bilayer of the cell and the other in that of the virion, so that cell-surface 222 
tetherin homodimerizes with virion-associated tetherin via disulfide bonds or 223 
via coiled-coil regions in the extracellular domain (Fitzpatrick et al., 2010). 224 
Thus, virions remain bound to the cell surface and are cross-linked to each 225 
other by tetherin.  226 
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HIV-1 Vpu is an integral class I membrane phosphoprotein (Cohen et al., 227 
1988) that promotes virion release from HIV-1 infected human cells that 228 
express tetherin (Klimkait et al., 1990; Neil et al., 2006; Neil et al., 2008; Van 229 
Damme et al., 2008). It has been shown to colocalize with tetherin (Neil et al., 230 
2008; Van Damme et al., 2008) and to reduce its cell-surface expression by 231 
targeting it for degradation (Van Damme et al., 2008; Miyagi et al., 2009; 232 
Douglas et al., 2009; Goffinet et al., 2009; Mitchell et al., 2009). A well-studied 233 
role of Vpu is to mediate the proteasomal degradation of the HIV-1 receptor 234 
CD4 in the ER through the recruitment of the β-transducin repeat-containing 235 
protein (βTrcP) subunit of the Skp1-cullin1-F-box (SCF) ubiquitin ligase 236 
complex (Bour et al., 1995; Margottin et al., 1998; Willey et al., 1992). βTrCP 237 
is also involved in the antagonism of tetherin because disruption of the 238 
interaction between βTrCP and the βTrCP binding motif in the cytoplasmic 239 
domain of Vpu reduces the capacity of Vpu to promote virus release (Mitchell 240 
et al., 2009; Mangeat et al., 2009; Douglas et al., 2009). Vpu serves as an 241 
adapter between βTrCP and tetherin. Tetherin and Vpu bind to each other 242 
through their transmembrane domains (Rong et al., 2009; Iwabu et al, 2009). 243 
It seems that Vpu sequesters  tetherin within the endolysosomal system either 244 
within the TGN after it has been synthesized or within recycling endosomes 245 
after natural endocytosis of tetherin from the cell surface has occurred 246 
(Mitchell et al., 2009; Dube et al., 2010). This intracellular sequestration is 247 
followed by partial lysosomal degradation of both tetherin and Vpu.   248 
Vpu is only encoded by a unique lineage of primate lentiviruses that include 249 
HIV-1 and the simian immunodeficiency viruses (SIVs) of chimpanzees (Pan 250 
troglodytes) (Cohen et al., 1988), Mona monkeys (Cercopithecus mona), 251 
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Mustached monkeys (C. cephus) and greater spot-nosed monkeys (C. 252 
nictitans), SIVcpz, SIVmon, SIVmus and SIVgsn, respectively (Courgnaud et al., 253 
2003).  SIVmon, SIVmus and SIVgsn Vpu counteract tetherins of their respective 254 
host species as well as macaque tetherins, but, with the exception of SIVgsn, 255 
not human tetherin (huTHN). Accordingly, non-human, non-chimpanzee 256 
tetherins are usually insensitive to antagonism by HIV-1 Vpu (Goffinet et al., 257 
2009; Gupta et al., 2009b; Jia et al., 2009; McNatt et al., 2009; Sauter et al., 258 
2009; Zhang et al., 2009). SIVcpz is the immediate precursor of HIV-1 and its 259 
Vpu shares a common ancestry with SIVmon/mus/gsn Vpu (Sauter et al., 2009). 260 
However, SIVcpz Vpu is non-functional against both chimpanzee tetherin 261 
(cpzTHN) and huTHN. Instead, in SIVcpz the accessory protein Nef has 262 
adopted a Vpu-like function. It is likely that, after cross-species transmission 263 
from chimpanzees to humans, HIV-1 Vpu has adapted to counteract huTHN, 264 
because huTHN is resistant to Nef due to a deletion in the cytoplasmic tail of 265 
huTHN (Sauter et al., 2009; Zhang et al., 2009). Species-specific tetherin 266 
antagonism by Nef is also conserved in SIVs of sooty mangabeys/rhesus 267 
macaques and African green monkeys, SIVsmm/mac and SIVagm, respectively. 268 
Like Vpu, Nef also induces cell-surface downregulation of monkey tetherins 269 
(Jia et al., 2009). Additionally to Vpu and Nef, the HIV-2 and SIVagmTan 270 
(SIVagm of the Tantalus monkey, Chlorocebus tantalus) envelope 271 
glycoproteins (Envs) possess anti-tetherin activities (Abada et al., 2005; 272 
Gupta et al., 2009a; Le Tortorec, 2009).  273 
Interestingly, in addition to lentiviruses, tetherin blocks the virion release from 274 
members of the alpha-, beta-, deltaretrovirus, spumaretrovirus, arenavirus 275 
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(Lassa) and filovirus (Ebola, Marburg) families (Sakuma et al., 2009; Jouvenet 276 
et al., 2009; Kaletsky et al., 2009).   277 
 278 
3. Significance of tetherin in felids 279 
 280 
Retroviruses have invaded members of the Felidae on multiple occasions. Of 281 
the 37 known species of felids, 21 species such as the African lion (Panthera 282 
leo), the North American puma (Puma concolor) or the domestic cat have 283 
been shown to harbour antibodies reactive to FIV and many of these species 284 
harbour viral sequences consistent with species-specific strains 285 
(VandeWoude and Apetrei, 2006; Troyer et al., 2008). In addition to FIV, 286 
domestic cats harbour gamma retroviruses such as exogenous and 287 
endogenous feline leukemia viruses (FeLVs) or RD114 and the 288 
spumaretrovirus FeFV (Reeves and O’Brien, 1984). In contrast to the high 289 
prevalence of FIV in different felid species, gamma retroviruses are, with the 290 
exception of sporadic cross-species transmission events, restricted to 291 
domestic cats (Benveniste and Todaro, 1975; Reeves and O’Brien, 1984), 292 
which suggests that they entered the domestic cat lineage after it had evolved 293 
10,000 years ago (Vigne et al., 2004). The abundance of different retroviruses 294 
in cats necessitates the presence of potent and broadly specific host 295 
restriction factors. However, as mentioned above, cats express a truncated 296 
and non-functional TRIM5 protein (McEwan et al., 2009) and their A3 proteins 297 
are counteracted by wild-type FIV and FeFV (Löchelt et al., 2005; Münk et al., 298 
2008; Stern et al., 2010; Zielonka et al., 2010). Therefore, their ability to 299 
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suppress retroviral replication may critically depend on the activity of a feline 300 
homologue of tetherin. 301 
 302 
4. Identification of a feline homologue of BST-2/tetherin 303 
 304 
Blast searches of the feline genome using known primate, rodent and canine 305 
tetherin sequences identified a candidate gene for a feline homologue of 306 
tetherin. The transcript was amplified from interferon-ω stimulated feline IL2-307 
dependent T cell (MYA-1) cDNA. The nucleotide sequence (Genbank 308 
accession HM461970) was analyzed and revealed 59% nucleic acid and 44% 309 
amino acid identity between cat tetherin (hereafter referred to as feTHN) and 310 
its human homologue and 77% nucleic acid and 60% amino acid identity to 311 
canine tetherin, transcript variant 2 (XM860510) (Figure 1). Tetherin 312 
configuration rather than its amino acid sequence has been shown to be 313 
critical for its antiviral activity (Perez-Caballero et al., 2009). Thus, we asked 314 
whether feTHN would adopt the same typical protein topology described for 315 
other tetherins (Ishikawa et al., 1995; Ohtomo et al., 1999, Kupzig et al., 316 
2003). A hydropathy plot and secondary structure predictions of the feTHN 317 
amino acid sequence confirmed the presence of an N-terminal 318 
transmembrane domain, which is followed by an alpha-helical region and a 319 
coiled-coil domain (Figure 1). The alpha-helical region contains three 320 
conserved cysteines (C59, C69, C97). Additionally, feTHN was predicted to 321 
contain a C-terminal GPI anchor signal sequence and the potential GPI 322 
anchor attachment site has been mapped to S161. Thus, both amino acid 323 
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sequence and topology described for different tetherins are conserved in 324 
feTHN.  325 
The expression levels of feTHN in feline T cell (MYA-1), fibroblast (AH927), 326 
kidney epithelioid (CrFK) and fetal embryo fibroblast-like (FEA) cell lines and 327 
the effect of treatment with type I interferons and IFN-γ (1000 U/ml) on its 328 
expression were examined by qRT-PCR. All cell lines showed a basal feTHN 329 
expression with FEA cells expressing approximately 10-fold lower levels 330 
compared to the other cell lines tested. Tetherin expression was inducible by 331 
type I IFN (α, ω) in all four cell lines, whereas treatment with IFN-γ had little 332 
effect on tetherin expression in MYA cells but up-regulated tetherin expression 333 
markedly in AH927, CrFK and FEA cells. In conclusion, feTHN shares the 334 
expression profile of huTHN.  335 
 336 
5. Antiviral activity of feline tetherin 337 
 338 
In order to assess the potency of feline tetherin to inhibit viral release, single-339 
cycle viral replication assays were performed. FIV(VSV-G)-GFP pseudotypes 340 
were produced by transfecting 293T cells with the FIV-based vectors FP93 341 
(Gagpol) and pGinSin (GFP) (Poeschla et al., 1998) and the vesicular 342 
stomatitis virus G glycoprotein (VSV-G)-encoding vector pMDG (Yee et al., 343 
1994)  in the presence or absence of feTHN. The pseudotypes were used to 344 
transduce CrFK cells and the viral titre was determined by flow cytometry. 345 
FeTHN caused a marked and dose-dependent reduction of the FIV(VSV-G)-346 
GFP titer (Figure 2A). Inhibition of viral release was confirmed by 347 
immunoblotting against viral p24 in the culture supernatants (Figure 2D). In 348 
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contrast to viral release, virus production was unaffected by the expression of 349 
feTHN. HIV-1 wild-type pseudotypes were produced as described above 350 
using the HIV-1-derived vector p8.2 (Gagpol) ans CSGW (GFP) (Naldini et al., 351 
1996) and pMDG. Pseudotypes of Vpu-deficient HIV-1 (HIV-1 ΔVpu) were 352 
generated using p8.91 (Gagpol) (Naldini et al., 1996), CSGW and pMDG.  353 
Feline tetherin was equally effective in blocking HIV-1 ΔVpu and HIV-1 wild-354 
type viral release (Figures 2B,C and 2D), suggesting that its activity was not 355 
counteracted by HIV-1 Vpu. This finding underlines the concept of species-356 
specificity of the tetherin-Vpu interaction (Yang et al., 2010).  357 
In contrast to the well-defined role of tetherin in preventing viral release, 358 
information on its potency to block viral replication and spread is sparse. To 359 
this end, CrFK cells were stably transduced with a feTHN expression 360 
construct and infected with low or high inputs of CrFK-tropic strains of FIV-Pco 361 
(CoLV) or FIV-Fca (Petaluma F14) and virus production monitored by RT 362 
assay. Surprisingly and in contrast to the marked inhibitory effect of tetherin 363 
on lentiviral pseudotype production, ectopic expression of tetherin did not 364 
inhibit virus production from FIV-infected CrFK cells. Instead, syncytium 365 
formation was enhanced in the tetherin-expressing cells compared with 366 
control cells as virions are trapped at the cell surface promoting cell-cell 367 
fusion. As FIV-Pco and FIV-Fca (Petaluma F14) are cell culture-adapted viral 368 
strains, we generated CrFK cells and CrFK-feTHN cells stably expressing the 369 
viral primary receptor CD134 (Shimojima et al., 2004) and studied the effect of 370 
feTHN on replication of the primary strains of FIV, GL8 and PPR. Again, 371 
feTHN did not influence the viral growth rate. In summary, these findings 372 
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suggest that feTHN is unable to prevent replication of cell-culture adapted and 373 
primary strains of FIV.  374 
 375 
6. Conclusion and future directions 376 
 377 
Overall, feline tetherin resembles human tetherin in amino acid sequence, 378 
protein topology and anti-viral activity. It is expressed in different feline cells in 379 
to a basic level and its expression can be significantly enhanced by treatment 380 
with type I or type II IFN. FeTHN exhibited a potent, dose-dependent block to 381 
retroviral particle release, which was not relieved by the HIV-1 accessory 382 
protein Vpu. In stark contrast to particle release, stable expression of feTHN 383 
had no effect on FIV replication and even increased the likelihood of cell-cell 384 
fusion events thus possibly promoting viral cell-to-cell spread. Given the fact 385 
that feTHN was expressed from a CMV promoter in both the transiently and 386 
stably transfected cells, these findings suggest that the number of tetherin 387 
molecules on the cell surface might be limited and that feTHN therefore has 388 
only a saturable capacity to prevent viral particle release from productively 389 
infected cells. In single-cycle replication assays, however, the amount of virus 390 
particles to be retained at the cell surface might be lower so that virus release 391 
can be controlled by tetherin.   392 
Indeed, there is evidence that Vpu-deficient HIV-1 can replicate in tissue 393 
culture with the same kinetics as wild-type virus (Strebel et al., 1988; 394 
Terwilliger et al., 1989; Klimkait et al., 1990) by shifting from a cell-free to a 395 
cell-to-cell mode of replication. As a consequence of this shift, viral replication 396 
was, in contrast to viral release, not inhibited. Further, it was recently shown 397 
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that in T cells infected with Vpu-defective HIV-1, but not wild-type HIV-1, virus 398 
envelope proteins accumulated on the cell surface due to the action of 399 
tetherin, which promoted formation of virological synapses (VS) and direct 400 
cell-to-cell spread of virions (Jolly et al., 2010). 401 
Future research should focus on the role of tetherin as a regulator of innate 402 
immunity. Tetherin has been shown to be a specific marker of type I IFN-403 
producing cells (IPCs) or plasmacytoid dendritic cells (pDCs) (Blasius et al., 404 
2006). These cells circulate through the blood and infiltrate lymph nodes that 405 
drain sites of infection. Viruses trigger Toll-like receptor (TLR) 7/9-induced 406 
production of large amounts of type I IFN and proinflammatory cytokines that 407 
activate anti-viral intrinsic, innate and adaptive immune responses (Colonna et 408 
al., 2004; Liu, 2005). A chronic activation of pDCs and continuous IFN 409 
production caused by lentivirus infection leads to immune dysregulation, T cell 410 
anergy and apoptosis (Tompkins and Tompkins, 2008). Tetherin has been 411 
shown to interact with the orphan receptor immunoglobin-like transcript (ILT7), 412 
which is expressed exclusively on pDCs (Cao et al., 2006). This interaction 413 
induces a negative feedback loop on the production of type I IFN and 414 
proinflammatory cytokine production and adjusts the magnitude of immune 415 
activation upon viral infection. Additionally, tetherin incorporation into the lipid 416 
envelopes of viral particles could enhance their uptake into professional 417 
antigen presenting cells (APCs).  418 
The elucidation of the role of feline tetherin in controlling replication of feline 419 
retroviruses in vivo by balancing immune responses will help to develop 420 
promising new approaches for the prevention and treatment of infections.   421 
 422 
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Figure 1. Amino acid sequence alignment of tetherins. The amino acid 1105 
sequences of feline, canine (transcript variant 2), human, rat and horse 1106 
tetherin are compared. Amino acids conserved between all tetherin orthologs 1107 
are highlighted in dark grey, those conserved between at least three 1108 
sequences in light grey. The positions of predicted protein domains are 1109 
indicated. The position of the transmembrane domain is marked by a blue bar 1110 
and the position of the coiled-coil domain, which contains the three conserved 1111 
cysteine residues, by a green bar. The length of the extracellular domain is 1112 
indicated by black arrows. The position of the potential GPI anchor attachment 1113 






Figure 2. Feline tetherin restricts FIV and HIV-1 particle release and is not 1119 
overcome by the HIV-1 accessory protein Vpu. (A) 293T cells were co-1120 
transfected with the FIV expression plasmids FP93 (Gagpol), pGinSin (GFP), 1121 
pMDG (VSV-G) and indicated amounts of feline tetherin (feTHN) plasmid 1122 
DNA. Infectious virus yield (expressed as percentage of infection) was 1123 
determined by transducing CrFK cells with the pseudotype-containing culture 1124 
supernatants of the producer cells and by quantifying the percentage of GFP-1125 
expressing cells using flow cytometry (± s.d., n=3). (B) 293T cells were co-1126 
 48 
transfected with the HIV-1 ΔVpu expression plasmids p8.91 (Gagpol), CSGW 1127 
(GFP) and pMDG and indicated amounts of feTHN plasmid DNA. The 1128 
infectious virus yield was determined as described for (A). (C) 293T cells were 1129 
co-transfected with the HIV-1 wild-type expression plasmids p8.2 (Gagpol), 1130 
CSGW (GFP) and pMDG and indicated amounts of feTHN plasmid DNA. The 1131 
infectious virus yield was determined as described for (A). (D) Western blot 1132 
analysis (anti-p24 capsid) of 293T cell lysates and virions after co-transfection 1133 
of FIV, HIV-1 ΔVpu or HIV-1 wild-type expression plasmids and varying 1134 
amounts of feTHN plasmid DNA. 1135 
 1136 
